Article Versions Notes

Giommoni E, Maiello E, Vaccaro V, Rondini E, Vivaldi C, Tortora G, Toppo L, Giordano G, Latiano TP, Lamperini C, et al. Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Current Oncology. 2021; 28(3):1761-1772. https://doi.org/10.3390/curroncol28030164

Giommoni, Elisa, Evaristo Maiello, Vanja Vaccaro, Ermanno Rondini, Caterina Vivaldi, Giampaolo Tortora, Laura Toppo, Guido Giordano, Tiziana Pia Latiano, Cinzia Lamperini, and et al. 2021. "Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)" Current Oncology 28, no. 3: 1761-1772. https://doi.org/10.3390/curroncol28030164

Giommoni, E., Maiello, E., Vaccaro, V., Rondini, E., Vivaldi, C., Tortora, G., Toppo, L., Giordano, G., Latiano, T. P., Lamperini, C., Pillozzi, S., Boni, L., Antonuzzo, L., & Di Costanzo, F. (2021). Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Current Oncology, 28(3), 1761-1772. https://doi.org/10.3390/curroncol28030164